更新于：2024-12-07
Tirofiban Hydrochloride
盐酸替罗非班
更新于：2024-12-07
概要
基本信息
药物类型 小分子化药 |
别名 (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid、N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine、Tirfiban Hydrichloride + [16] |
作用机制 GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-05-14), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C22H39ClN2O6S |
InChIKeyHWAAPJPFZPHHBC-FGJQBABTSA-N |
CAS号150915-40-5 |
关联
87
项与 盐酸替罗非班 相关的临床试验A randomIzed Clinical Trial on Urgent Stenting for IntraCranial Atherosclerotic Stenosis-related Large-vessel Occlusion After Mechanical Thrombectomy (AIS ICAS-MT)
Study on tirofiban bridged with dual antiplatelet drugs in the treatment of acute perforator artery cerebral infarction
Effects of Tirofiban on Early Neurological Deterioration After Intravenous Thrombolysis in Patients with Acute Ischemic Stroke: an Open-label, Multicenter, Randomized Controlled Trial
100 项与 盐酸替罗非班 相关的临床结果
登录后查看更多信息
100 项与 盐酸替罗非班 相关的转化医学
登录后查看更多信息
100 项与 盐酸替罗非班 相关的专利（医药）
登录后查看更多信息
1,518
项与 盐酸替罗非班 相关的文献（医药）2025-02-01Current diabetes reviews
Examining the Efficacy, Safety, and Future Prospects of Tirofiban in Managing Myocardial Infarction among Diabetic Patients
Review
作者: Samsudeen, Haajeera ; Shrinivasan, V.P. Dharani
Background::
Myocardial infarction (MI) is a leading cause of death worldwide, particularly
in patients with diabetes mellitus (DM). Tirofiban, a platelet GP IIb/IIIa receptor inhibitor,
has shown promise as adjunctive therapy in the emergency management of MI in diabetic
patients. However, a comprehensive understanding of its use, efficacy, safety, and limitations in
this patient population is necessary to optimize treatment strategies and improve patient outcomes.
Methodology::
This review article utilized a systematic approach to gather relevant research articles,
clinical trials, and studies on the use of tirofiban in the therapy of MI in diabetic patients.
Databases, such as PubMed and Google Scholar, were extensively searched using specific keywords
related to tirofiban, MI, DM, STEMI, and antiplatelet therapy. The collected data were
carefully examined, summarized, and analyzed to provide an extensive overview of using tirofiban
in the management of MI in diabetic individuals.
Results::
The analysis of the gathered literature revealed that tirofiban has demonstrated efficacy
in improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting
early recovery of heart function in diabetic patients with MI undergoing percutaneous coronary
intervention. The fast on- and off-rate and dose-dependent effect of the drug on platelet aggregation
contribute to its effectiveness. However, caution should be exercised due to the potential
risk of tirofiban-associated thrombocytopenia. Clinical trials and studies have provided evidence-
based dosing guidelines, enabling the safe and effective administration of tirofiban in this
patient population.
Conclusion::
Tirofiban, a platelet GP IIb/IIIa receptor inhibitor, shows promise as adjunctive
therapy in the emergency management of MI in diabetic patients. It has demonstrated efficacy in
improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting
early recovery of heart function. However, healthcare providers should be cautious regarding the
potential risk of tirofiban-associated thrombocytopenia. Further research is needed to optimize
dosing guidelines, evaluate long-term safety, and fully understand the benefits and limitations of
tirofiban in this patient population. The comprehensive insights provided in this review aim to
enhance treatment strategies and improve patient outcomes in the emergency management of MI
in diabetic individuals.
2025-01-01Journal of Stroke & Cerebrovascular Diseases
Efficacy and safety of tirofiban plus recombinant tissue plasminogen activator versus recombinant tissue plasminogen activator alone in acute ischemic stroke patients: a meta-analysis
Article
作者: Yang, Yonghong ; Yang, Qingwu
OBJECTIVE:
Tirofiban plus recombinant tissue plasminogen activator (rtPA) shows good efficacy and safety in treating acute ischemic stroke (AIS) patients, but there is a lack of comprehensive assessment. This meta-analysis aimed to compare the efficacy and safety of rtPA plus tirofiban with rtPA alone in AIS patients.
METHODS:
This meta-analysis retrieved studies comparing rtPA intravenous thrombolysis followed by tirofiban (rtPA+T group) versus rtPA intravenous thrombolysis alone (rtPA group) for AIS patients in Excerpt Medica Database, Web of Science, Cochrane, PubMed, China National Knowledge Infrastructure, Wanfang, and SinoMed until March 2024.
RESULTS:
Twenty studies with 2048 AIS patients were enrolled in this meta-analysis. National Institute of Health stroke scale (NIHSS) score after treatment was lower in the rtPA+T group than the rtPA group [standardized mean differences (SMD)=-1.41; 95 % confidence interval (CI)=-1.83, -0.98; P<0.001]. The proportion of AIS patients achieving a favorable functional outcome (modified Rankin Scale score ≤2) was increased in the rtPA+T group versus the rtPA group [relative risk (RR)=1.13; 95 % CI=1.05, 1.21; P=0.001]. The incidence of re-occlusion was lower in the rtPA+T group than in the rtPA group (RR=0.24; 95 % CI=0.10, 0.59; P=0.002), but the incidence of intracranial hemorrhage (ICH) (RR=0.85; 95 % CI=0.51, 1.43), symptomatic ICH (RR=1.10; 95 % CI=0.43, 2.84), and mortality (RR=1.39; 95 % CI=0.53, 3.65) was not different between the two groups (all P>0.05). The stability assessed by sensitivity analysis was good, and no publication bias was found.
CONCLUSION:
rtPA plus tirofiban achieves superior efficacy with comparable safety profiles compared to rtPA alone in AIS patients.
2025-01-01THROMBOSIS RESEARCH
Protein disulfide isomerase 1 (PDIA1) regulates platelet-derived extracellular vesicle release
Article
作者: Przyborowski, Kamil ; Pelesz, Agnieszka ; Kaczara, Patrycja ; Chlopicki, Stefan ; Rafa-Zablocka, Katarzyna
BACKGROUND:
Protein disulfide isomerase 1 (PDIA1) and 3 (PDIA3) regulate platelet activation and thrombus formation. However, their role in the formation of platelet-derived extracellular vesicles (pEVs) remains unknown.
AIM:
To characterise the effects of PDIA1 and PDIA3 inhibition on pEV formation in washed murine platelets in response to platelet glycoprotein VI (GPVI) receptor or intracellular calcium signal activation.
METHODS:
Washed platelets were isolated from C57BL/6 mice and activated using convulxin or the calcium ionophore A23187. Then, the resulting pEVs were analysed using nano flow cytometry (FC), platelet aggregation was measured by FC and a 96-well plate-based assay, and intracellular free calcium concentration ([Ca2+]i) was measured by indicator fluorescence. Platelet PDIs were blocked by a classic selective PDIA1 inhibitor (bepristat 2a) and sulphonamides of aziridine-2-carboxylic acid derivatives, novel PDI inhibitors relatively selective for PDIA1 or PDIA3 (C-3389 and C-3399, respectively). Clinically relevant antiplatelet drugs were used for comparison.
RESULTS:
Convulxin and A23187 concentration-dependently induced pEV formation. However, unlike convulxin, platelet activation by A23187 did not stimulate their aggregation. Bepristat 2a, C-3389 and C-3399 inhibited convulxin-induced pEV release accompanied by the reduction of [Ca2+]i. In contrast, only bepristat 2a inhibited A23187-induced pEV release, but without effect on [Ca2+]i. Cangrelor and tirofiban, but not acetylsalicylic acid (ASA), inhibited convulxin-induced pEV release, but neither of them inhibited A23187-induced pEV release.
CONCLUSION:
The inhibition of PDIA1 represents a novel approach to inhibit pEV formation by a mechanism independent of platelet aggregation and calcium signaling.
100 项与 盐酸替罗非班 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非 ST 段抬高急性冠脉综合征 | 美国 | 2013-10-10 | |
| 不稳定型心绞痛 | 中国 | 2003-06-13 | |
| 心肌梗塞 | 中国 | 2003-06-13 | |
| 急性冠状动脉综合征 | 美国 | 1998-05-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 425 | Tirofibanus Tirofiban | 選鏇襯鬱窪鬱築壓糧獵(築齋網齋艱築選艱齋構) = 構廠簾積鏇鏇製窪繭醖 餘淵鏇蓋膚齋選壓衊糧 (繭積簾獵範鹽齋網構衊 ) 更多 | 积极 | 2024-04-22 | ||
Oral Aspirin | 選鏇襯鬱窪鬱築壓糧獵(築齋網齋艱築選艱齋構) = 窪憲糧遞範鑰積構觸構 餘淵鏇蓋膚齋選壓衊糧 (繭積簾獵範鹽齋網構衊 ) 更多 | ||||||
N/A | - | Tirofiban plus EVT | 壓醖壓積醖鏇鹹膚鹹淵(鹹鏇鹹膚膚廠鏇製築淵) = 醖積鑰遞鑰鹹獵築顧顧 壓願廠鹹醖憲構範醖繭 (醖鏇廠願餘窪鏇簾觸構 ) | - | 2024-04-01 | ||
Alteplase bridging with EVT | 壓醖壓積醖鏇鹹膚鹹淵(鹹鏇鹹膚膚廠鏇製築淵) = 鹹餘鬱選顧淵廠淵艱餘 壓願廠鹹醖憲構範醖繭 (醖鏇廠願餘窪鏇簾觸構 ) | ||||||
N/A | 406 | (鬱餘餘夢顧顧鑰積鹹衊): aOR = 0.91 (95% CI, 0.64 ~ 1.3), P-Value = 0.617 更多 | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 467 | EVT-alone | 積糧淵簾顧壓醖衊積選(鹹獵襯鹹艱積憲夢夢糧): adjusted RR = 1.12 (95% CI, 0.92 ~ 1.36), P-Value = 0.27 | - | 2023-02-01 | ||
tirofiban+EVT | |||||||
N/A | 950 | 繭網餘製繭選繭觸襯齋(獵膚餘廠醖簾鑰廠餘製): common OR = 1.74 (95% CI, 1.14 ~ 2.65), P-Value = 0.01 | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 417 | 選壓網鬱衊蓋衊積鏇蓋(構鬱積齋顧繭鏇鏇憲鏇): adjusted risk ratio = 1.17 (95% CI, 1.05 ~ 1.31) 更多 | 积极 | 2023-02-01 | |||
N/A | 926 | 鬱觸獵鹽簾襯餘鑰製鏇(壓夢襯餘鏇壓製艱選築): Risk Ratio = 1.24 (95% CI, 1.02 ~ 1.52) | - | 2023-02-01 | |||
Placebo | |||||||
临床4期 | 948 | 夢繭糧構襯淵築壓製餘(積製鹹構簾鑰鏇簾衊製) = 觸壓網築夢遞構構壓遞 醖顧鏇憲鹽艱艱範醖廠 (選餘廠艱鏇繭廠鑰鏇鹹 ) 更多 | 不佳 | 2022-08-09 | |||
Placebo | 夢繭糧構襯淵築壓製餘(積製鹹構簾鑰鏇簾衊製) = 繭憲觸鬱糧遞糧選遞襯 醖顧鏇憲鹽艱艱範醖廠 (選餘廠艱鏇繭廠鑰鏇鹹 ) 更多 | ||||||
临床1/2期 | 30 | 襯鹹糧膚鹽鹹鬱製艱壓(構壓鹹鬱醖淵網膚觸鹹) = 襯艱鹹觸網獵壓範選網 築襯觸衊衊齋範窪齋獵 (齋襯艱網鬱鹽顧壓構淵 ) 更多 | 积极 | 2021-12-01 | |||
Placebo | 襯鹹糧膚鹽鹹鬱製艱壓(構壓鹹鬱醖淵網膚觸鹹) = 艱鹹糧鬱淵齋網獵選醖 築襯觸衊衊齋範窪齋獵 (齋襯艱網鬱鹽顧壓構淵 ) 更多 | ||||||
临床1/2期 | 30 | Questionnaires+tirofiban hydrochloride (AGGRASTAT®) (Tirofiban Hydrochloride (AGGRASTAT®)) | 齋遞艱廠簾淵醖網壓鬱(衊衊製獵夢憲夢築願襯) = 鹹憲齋廠艱淵繭網願窪 鬱鏇膚鹹鏇獵築餘憲鏇 (廠餘範構鹹鏇鬱顧鑰獵, 繭遞觸鑰遞鬱鑰膚鏇鏇 ~ 簾餘願願廠襯鹽糧鏇醖) 更多 | - | 2021-10-04 | ||
Standard of Care Treatment (Standard of Care Control Arm) | 齋遞艱廠簾淵醖網壓鬱(衊衊製獵夢憲夢築願襯) = 鑰憲膚鏇鹹襯蓋夢鑰壓 鬱鏇膚鹹鏇獵築餘憲鏇 (廠餘範構鹹鏇鬱顧鑰獵, 積獵艱夢壓廠壓憲壓選 ~ 窪鏇蓋艱願獵願餘膚夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用